Ninlaro

Active Ingredient(s): Ixazomib
FDA Approved: * November 20, 2015
Pharm Company: * MILLENNIUM PHARMS
Category: Cancer

Ixazomib (trade name Ninlaro) is a drug for the treatment of multiple myeloma,[2] a type of white blood cell cancer,[3] in combination with other drugs. It is taken by mouth in the form of capsules. Common side effects include diarrhea, constipation and low platelet count. Like the older bortezomib (which can only be given by injection), it acts as a proteasome inhibitor, has orphan drug status in the US and Europe, and is a boronic acid derivative. The drug wa... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Ninlaro 2.3 mg Oral Capsule
NDC: 63020-078
Labeler:
Millennium Pharmaceuticals, Inc.
Ninlaro 3 mg Oral Capsule
NDC: 63020-079
Labeler:
Millennium Pharmaceuticals, Inc.
Ninlaro 4 mg Oral Capsule
NDC: 63020-080
Labeler:
Millennium Pharmaceuticals, Inc.
Ninlaro 2.3 mg Oral Capsule
NDC: 63020-230
Labeler:
Millennium Pharmaceuticals, Inc.
Ninlaro 3 mg Oral Capsule
NDC: 63020-390
Labeler:
Millennium Pharmaceuticals, Inc.
Ninlaro 4 mg Oral Capsule
NDC: 63020-400
Labeler:
Millennium Pharmaceuticals, Inc.